#35
Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
The IRS’s response to Section 280E tax deduction arguments directly impacts cannabis business profitability and operational costs, which can influence product pricing and patient access to legal cannabis. Clinicians should understand that tax burden on dispensaries may affect whether patients can afford cannabis treatments or whether certain products remain available in their market. If Section 280E is modified through regulatory or legislative changes prompted by these IRS responses, it could reduce business costs and potentially improve patient access to standardized, regulated cannabis products.
The IRS has issued its first formal response to industry arguments challenging Internal Revenue Code Section 280E, which prohibits tax deductions for businesses trafficking in Schedule I controlled substances, including cannabis. The cannabis industry has increasingly argued that cannabis should be reclassified to Schedule III based on a Department of Health and Human Services study supporting this change, which would theoretically allow businesses to claim standard business tax deductions. However, the IRS’s position indicates that Schedule I classification remains the controlling legal standard for tax purposes regardless of pending reclassification discussions, meaning cannabis businesses cannot currently deduct ordinary business expenses from federal taxes. This creates a significant and continuing financial burden for legal cannabis retailers and producers operating in compliant state markets. Clinicians should be aware that the high tax burden on cannabis businesses contributes to elevated retail prices and supply chain costs that may limit patient access to cannabis products, particularly for lower-income patients. Physicians should understand that cannabis scheduling and tax policy directly impact their patients’ ability to afford legal products and may inadvertently incentivize use of unregulated alternatives.
“The IRS’s position on 280E tax deductions reflects a deeper problem: we cannot practice evidence-based medicine or build a legitimate pharmaceutical industry when federal scheduling prevents us from conducting the research that would settle these questions definitively. Until cannabis moves off Schedule I, physicians like myself will continue operating in a legal gray zone that ultimately harms patients who deserve transparent, regulated access to treatments we’re already prescribing.”
? The IRS’s first formal response to cannabis industry arguments regarding Section 280E tax deductions highlights an ongoing tension between federal scheduling and business operations that clinicians should understand when counseling patients about the cannabis market and product safety. While the rescheduling debate hinges partly on HHS pharmacological evidence, the tax code implications create financial pressure on cannabis businesses that may inadvertently affect product quality, testing standards, and consumer safety—factors that influence what patients are actually purchasing and consuming. Clinicians need awareness that businesses operating under severe tax burdens may have reduced resources for third-party testing, quality assurance, and adverse event reporting, potentially obscuring the true safety and efficacy profile of cannabis products their patients use. Additionally, the current regulatory fragmentation means that clinical guidance must remain cautious and individualized, since product composition and contamination risks vary widely depending on state and local oversight. Understanding these industry and tax pressures provides helpful context when discussing
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
